Characteristics of basal cytokeratin expression in breast cancer

Breast Cancer Research and Treatment

Volumn 139, Issue 1, 2013, Pages 23-37

  Alshareeda, Alaa T ^a,b   Soria, Daniele ^a   Garibaldi, Jonathan M ^a   Rakha, Emad ^a   Nolan, Christopher ^a   Ellis, Ian O ^a   Green, Andrew R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Ministry of Education Saudi Arabia   (Saudi Arabia)

Author keywords

Basal cytokeratins; Basal like breast cancer; Clustering analysis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR INVASION; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CLUSTER ANALYSIS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATIN-14; KERATIN-17; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877575739     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2518-x     Document Type: Article

References (40)

1. Bhargava R et al (2008) CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. Am J Clin Pathol 130(5):724-730
2. Altmannsberger M et al (1986) Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol 51(3):265-275
3. Dairkee SH et al (1987) Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 10(1):11-20
4. Moll R et al (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31(1):11-24
5. Nagle RB et al (1986) Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34(7):869-881
6. Millikan RC et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139
7. Gusterson BA et al (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7(4):143-148
8. Malzahn K et al (1998) Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433(2):119-129
9. Paredes J et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450(1):73-80
10. Ribeiro-Silva A et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47(5):458-466
11. Parry S et al (2008) Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 61(9):1045-1050
12. Nalwoga H et al (2008) Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS 116(6):515-525
13. Rodriguez-Pinilla SM et al (2007) Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60(9):1006-1012
14. Ding Y, Ruan Q (2006) The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technol Med Sci 26(4):405-407
15. Kordek R et al (2010) Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 29:39
16. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
17. Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205-262
18. Rakha EA et al (2009) Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 113(3):411-422
19. Madjd Z et al (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200(5):633-639
20. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568-2581
21. Alshareeda AT et al (2012) Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast Cancer Res Treat 134(2):519-529
22. Garc T et al (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:472-480
23. Aleskandarany MA et al (2011) Prognostic value of proliferation assay in the luminal, HER2 positive and triple negative biological classes of breast cancer. Breast Cancer Res 14(1):R3
24. Soria D et al (2010) A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 40(3):318-330
25. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
26. Rakha EA et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149-3156
27. Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492-2502
28. Nielsen TO et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-5374
29. Mohammadizadeh F et al (2009) Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. Indian J Med Sci 63(4):152-162
30. Eerola H et al (2008) Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 10(1):R17
31. Bocker W et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737-746
32. Fulford LG et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4
33. Rouzier R et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-5685
34. Rakha EA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302-2310
35. Fuqua SA et al (1993) The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 26(2):191-202
36. Potemski P et al (2005) Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69(6):478-485
37. Cheang MC et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368-1376
38. Bertucci F et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123(1):236-240
39. Calza S et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8(4):R34
40. Yang XR et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439-443